Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action. (2nd September 2017)

• Record Type: Journal Article
• Authors: De Cicco, Simona; Immediata, Valentina; Romualdi, Daniela; Policola, Caterina; Tropea, Anna; Di Florio, Christian; Tagliaferri, Valeria; Scarinci, Elisa; Della Casa, Silvia; Lanzone, Antonio; Apa, Rosanna
• Is Part Of: Gynecological endocrinology. Volume 33:Number 9(2017)
• Page Start: 698
• Page End: 701
• Publication Date: 2017-09-02
• Subjects: PCOS -- alpha-lipoic acid -- myoinositol -- menstrual pattern -- hyperandrogenism; Endocrine gynecology -- Periodicals; Generative organs, Female -- Diseases -- Periodicals; 618.1
• DOI: 10.1080/09513590.2017.1313972
• Languages: English
• ISSNs: 0951-3590

Abstract

Abstract: The aim of our study was to investigate the effects of a combined treatment with alpha-lipoic acid (ALA) and myoinositol (MYO) on clinical, endocrine and metabolic features of women affected by polycystic ovary syndrome (PCOS). In this pilot cohort study, forty women with PCOS were enrolled and clinical, hormonal and metabolic parameters were evaluated before and after a six-months combined treatment with ALA and MYO daily. Studied patients experienced a significant increase in the number of cycles in six months ( p < 0.01). The free androgen index (FAI), the mean androstenedione and DHEAS levels significantly decreased after treatment ( p < 0.05). Mean SHBG levels significantly raised ( p < 0.01). A significant improvement in mean Ferriman–Gallwey (F–G) score ( p < 0.01) and a significant reduction of BMI ( p < 0.01) were also observed. A significant reduction of AMH levels, ovarian volume and total antral follicular count were observed in our studied women ( p < 0.05). No significant changes occurred in gluco-insulinaemic and lipid parameters after treatment. The combined treatment of ALA and MYO is able to restore the menstrual pattern and to improve the hormonal milieu of PCOS women, even in the absence of apparent changes in insulin metabolism.